DDInter298 DDInter1482
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases [FDA Label]. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing _Enterobacteriaceae_. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is palliated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Carboplatin {u} (Compound) causes {v} (Side Effect) Extravasation
Extravasation {u} (Side Effect) is caused by {v} (Compound) Iohexol
Iohexol {u} may lead to a major life threatening interaction when taken with {v} Plazomicin
Carboplatin {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plazomicin
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is palliated by Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Carboplatin (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Plazomicin
Carboplatin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin